{
    "nctId": "NCT02658708",
    "briefTitle": "Bright Light on Fatigue in Women Being Treated for Breast Cancer",
    "officialTitle": "Bright Light on Fatigue in Women Being Treated for Breast Cancer: A Pilot Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Breast Cancer, Cancer of Breast, Cancer of the Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 19,
    "primaryOutcomeMeasure": "Feasibility of implementing a bright light intervention as measured by estimating completion of scheduled PSG recording",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 21 years of age or older\n* Newly diagnosed with stage I-III breast cancer\n* Scheduled to receive 21-day cycles of intravenous chemotherapy\n* Experiencing disrupted sleep (determined by Pittsburgh Sleep Quality Index)\n* Morning or evening types (determined by Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ)\n* Sighted\n* Mentally competent to consent\n* Able to under English\n\nExclusion Criteria:\n\n* Concurrent malignancy\n* Undergoing other cancer treatments\n* Engage in shift work or travel across more than 3 time zones within 2 weeks prior to study\n* Known history of seasonal affective disorder or substance abuse\n* Current diagnosis of major Axis I psychiatric disorders, neurological impairments, or muscular dystrophies\n* Regularly use steroid or other immunosuppressive medications\n* Take prescribed sedative hypnotics or sleep medications because these conditions may affect fatigue and/or sleep/wake patterns.\n* Have eye conditions (glaucoma or retinal disease), problems triggered by bright light (e.g. migraine), or take photosensitizing medications (e.g. some porphyrin drugs, antipsychotics, antiarrhythmic agents)",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}